Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic HER2+ Advanced Breast Cancer”

666 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 666 results

Testing effectiveness (Phase 2)WithdrawnNCT03326258
What this trial is testing

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB Positive+15 more
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT03854903
What this trial is testing

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Who this might be right for
Metastatic Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor Positive Breast Cancer
Georgetown University 19
Large-scale testing (Phase 3)Ended earlyNCT00508274
What this trial is testing

Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 52
Testing effectiveness (Phase 2)Study completedNCT03839823
What this trial is testing

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 222
Early research (Phase 1)Study completedNCT01097460
What this trial is testing

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Who this might be right for
Breast Neoplasms
Merrimack Pharmaceuticals 16
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05953168
What this trial is testing

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 69
Testing effectiveness (Phase 2)Study completedNCT02732119
What this trial is testing

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 104
Testing effectiveness (Phase 2)UnknownNCT04963595
What this trial is testing

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Zhiyong Yu 100
Early research (Phase 1)Looking for participantsNCT04360941
What this trial is testing

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerLocally Advanced Breast CancerRecurrent Breast Cancer+3 more
Royal Marsden NHS Foundation Trust 45
Large-scale testing (Phase 3)Looking for participantsNCT07205822
What this trial is testing

Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 100
Testing effectiveness (Phase 2)Study completedNCT02188745
What this trial is testing

ER Reactivation Therapy for Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Dartmouth-Hitchcock Medical Center 19
Early research (Phase 1)Study completedNCT01245205
What this trial is testing

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more
National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)Looking for participantsNCT06042894
What this trial is testing

SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 58
Large-scale testing (Phase 3)UnknownNCT02404051
What this trial is testing

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerHormone Receptor Positive Tumor+2 more
Consorzio Oncotech 745
Testing effectiveness (Phase 2)Looking for participantsNCT06642545
What this trial is testing

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 40
Early research (Phase 1)Ended earlyNCT02598427
What this trial is testing

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

Who this might be right for
HER2 Positive Untreated Metastatic Breast CancerAsymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer
Kimberly Blackwell 1
Testing effectiveness (Phase 2)Study completedNCT04300790
What this trial is testing

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

Who this might be right for
Breast Cancer
MedSIR 69
Testing effectiveness (Phase 2)Looking for participantsNCT06445400
What this trial is testing

BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 120
Testing effectiveness (Phase 2)Study completedNCT00303992
What this trial is testing

Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
University of California, San Francisco 9
Testing effectiveness (Phase 2)Ended earlyNCT01980277
What this trial is testing

Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer

Who this might be right for
Breast Cancer
Institut Paoli-Calmettes 68
Load More Results